Xencor, Inc Income (Loss) from Equity Method Investments
Xencor, Inc (XNCR) reported Income (Loss) from Equity Method Investments of $26.66 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2021-11-08
- Xencor, Inc income (loss) from equity method investments for the quarter ending 2020-12-31 was $22.07M.
- Xencor, Inc income (loss) from equity method investments for the quarter ending 2020-09-30 was $0.00.
- Xencor, Inc income (loss) from equity method investments for the quarter ending 2020-06-30 was $0.00.
- Xencor, Inc income (loss) from equity method investments for the quarter ending 2020-03-31 was $4.59M.
- Xencor, Inc income (loss) from equity method investments for fiscal 2020 was $26.66M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2020-12-31 | $22.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $22.07M derived: sum of 2 quarters · filed 2021-11-08 | $22.07M derived: sum of 3 quarters · filed 2021-11-08 | $26.66M 10-K · filed 2021-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $4.59M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $4.59M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $4.59M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |